These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 9834817)

  • 1. Oxaliplatin: a review of preclinical and clinical studies.
    Raymond E; Chaney SG; Taamma A; Cvitkovic E
    Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Oxaliplatin: the first DACH platinum in clinical practice].
    Soulié P; Raymond E; Brienza S; Cvitkovic E
    Bull Cancer; 1997 Jun; 84(6):665-73. PubMed ID: 9295871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.
    Brienza S; Bensmaïne MA; Soulié P; Louvet C; Gamelin E; François E; Ducreux M; Marty M; André T; de Braud F; Bleiberg H; Ségal V; Itzhaki M; Cvitkovic E
    Ann Oncol; 1999 Nov; 10(11):1311-6. PubMed ID: 10631458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.
    Simpson D; Dunn C; Curran M; Goa KL
    Drugs; 2003; 63(19):2127-56. PubMed ID: 12962525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of oxaliplatin monotherapy: phase II trials in advanced colorectal cancer.
    Becouarn Y; Rougier P
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):23-31. PubMed ID: 9609105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin: a review of its use in the management of metastatic colorectal cancer.
    Wiseman LR; Adkins JC; Plosker GL; Goa KL
    Drugs Aging; 1999 Jun; 14(6):459-75. PubMed ID: 10408744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin clinical activity: a review.
    Misset JL; Bleiberg H; Sutherland W; Bekradda M; Cvitkovic E
    Crit Rev Oncol Hematol; 2000 Aug; 35(2):75-93. PubMed ID: 10936465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
    Janinis J; Papakostas P; Samelis G; Skarlos D; Papagianopoulos P; Fountzilas G
    Ann Oncol; 2000 Feb; 11(2):163-7. PubMed ID: 10761750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin (L-OHP): a new reality in colorectal cancer.
    Bleiberg H
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):1-3. PubMed ID: 9647611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA drug approval summaries: oxaliplatin.
    Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
    Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
    Vermorken JB
    Int J Gynecol Cancer; 2001; 11 Suppl 1():21-30. PubMed ID: 11488999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
    Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
    Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
    Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
    Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.
    Wasserman E; Sutherland W; Cvitkovic E
    Clin Colorectal Cancer; 2001 Nov; 1(3):149-53. PubMed ID: 12450427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of oxaliplatin in colorectal cancer.
    O'Dwyer PJ; Johnson SW
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):78-87. PubMed ID: 12802798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ongoing and unsaid on oxaliplatin: the hope.
    Cvitkovic E
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):8-11. PubMed ID: 9647613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.
    Chollet P; Bensmaïne MA; Brienza S; Deloche C; Curé H; Caillet H; Cvitkovic E
    Ann Oncol; 1996 Dec; 7(10):1065-70. PubMed ID: 9037366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.